Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

Mark D. Pescovitz, Stuart Knechtle, Steven R. Alexander, Paul Colombani, Tom Nevins, Keith Nieforth, M. René Bouw

Research output: Contribution to journalArticle

Abstract

This study examined the safety and pharmacokinetics/pharmacodynamics of daclizumab in combination with mycophenolate mofetil (or azathioprine), corticosteroids, and cyclosporine or tacrolimus, in 61 pediatric renal allograft recipients in three age groups: less than or equal to five yr (n = 18), 6-12 yr (n = 18), and 13-17 yr (n = 25). The dosing regimen was daclizumab 1.0 mg/kg before transplantation, followed by four biweekly doses. The pharmacokinetics of daclizumab were described using NONMEM software. Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 μg/mL (2.48-8.78), 4.54 μg/mL (1.79-18.7), and 4.94 μg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively. Steady-state median (range) daclizumab exposures were 2040 mg·h/mL (1585-3778), 2757 mg·h/mL (1873-3494) and 3297 mg·h/mL (1705-6453), respectively. Saturation of the IL-2R occurred rapidly and was maintained for greater than or equal to three months after transplantation. Daclizumab was generally well-tolerated with no acute allergic or anaphylactic reactions, deaths or malignancies during the study. The proportion of patients who developed acute rejection at six and 12 months was 8.5% and 16.7%, respectively. This study shows that adding daclizumab at 1 mg/kg to standard immunosuppressive therapy provides safe and effective IL-2R blockade.

Original languageEnglish (US)
Pages (from-to)447-455
Number of pages9
JournalPediatric Transplantation
Volume12
Issue number4
DOIs
StatePublished - Jun 2008

Fingerprint

Pharmacokinetics
Pediatrics
Kidney
Safety
Age Groups
Transplantation
Mycophenolic Acid
Azathioprine
Tacrolimus
Anaphylaxis
Immunosuppressive Agents
daclizumab
Transplant Recipients
Cyclosporine
Allografts
Adrenal Cortex Hormones
Hypersensitivity
Software
Neoplasms

Keywords

  • Children
  • Immunosuppression
  • Interleukin 2 receptor
  • Kidney transplantation
  • Monoclonal antibody
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Pescovitz, M. D., Knechtle, S., Alexander, S. R., Colombani, P., Nevins, T., Nieforth, K., & Bouw, M. R. (2008). Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatric Transplantation, 12(4), 447-455. https://doi.org/10.1111/j.1399-3046.2007.00830.x

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. / Pescovitz, Mark D.; Knechtle, Stuart; Alexander, Steven R.; Colombani, Paul; Nevins, Tom; Nieforth, Keith; Bouw, M. René.

In: Pediatric Transplantation, Vol. 12, No. 4, 06.2008, p. 447-455.

Research output: Contribution to journalArticle

Pescovitz, MD, Knechtle, S, Alexander, SR, Colombani, P, Nevins, T, Nieforth, K & Bouw, MR 2008, 'Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients', Pediatric Transplantation, vol. 12, no. 4, pp. 447-455. https://doi.org/10.1111/j.1399-3046.2007.00830.x
Pescovitz, Mark D. ; Knechtle, Stuart ; Alexander, Steven R. ; Colombani, Paul ; Nevins, Tom ; Nieforth, Keith ; Bouw, M. René. / Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. In: Pediatric Transplantation. 2008 ; Vol. 12, No. 4. pp. 447-455.
@article{298fcf6d4a924e13b1b919d95cca019b,
title = "Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients",
abstract = "This study examined the safety and pharmacokinetics/pharmacodynamics of daclizumab in combination with mycophenolate mofetil (or azathioprine), corticosteroids, and cyclosporine or tacrolimus, in 61 pediatric renal allograft recipients in three age groups: less than or equal to five yr (n = 18), 6-12 yr (n = 18), and 13-17 yr (n = 25). The dosing regimen was daclizumab 1.0 mg/kg before transplantation, followed by four biweekly doses. The pharmacokinetics of daclizumab were described using NONMEM software. Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 μg/mL (2.48-8.78), 4.54 μg/mL (1.79-18.7), and 4.94 μg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively. Steady-state median (range) daclizumab exposures were 2040 mg·h/mL (1585-3778), 2757 mg·h/mL (1873-3494) and 3297 mg·h/mL (1705-6453), respectively. Saturation of the IL-2R occurred rapidly and was maintained for greater than or equal to three months after transplantation. Daclizumab was generally well-tolerated with no acute allergic or anaphylactic reactions, deaths or malignancies during the study. The proportion of patients who developed acute rejection at six and 12 months was 8.5{\%} and 16.7{\%}, respectively. This study shows that adding daclizumab at 1 mg/kg to standard immunosuppressive therapy provides safe and effective IL-2R blockade.",
keywords = "Children, Immunosuppression, Interleukin 2 receptor, Kidney transplantation, Monoclonal antibody, Pharmacokinetics",
author = "Pescovitz, {Mark D.} and Stuart Knechtle and Alexander, {Steven R.} and Paul Colombani and Tom Nevins and Keith Nieforth and Bouw, {M. Ren{\'e}}",
year = "2008",
month = "6",
doi = "10.1111/j.1399-3046.2007.00830.x",
language = "English (US)",
volume = "12",
pages = "447--455",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

AU - Pescovitz, Mark D.

AU - Knechtle, Stuart

AU - Alexander, Steven R.

AU - Colombani, Paul

AU - Nevins, Tom

AU - Nieforth, Keith

AU - Bouw, M. René

PY - 2008/6

Y1 - 2008/6

N2 - This study examined the safety and pharmacokinetics/pharmacodynamics of daclizumab in combination with mycophenolate mofetil (or azathioprine), corticosteroids, and cyclosporine or tacrolimus, in 61 pediatric renal allograft recipients in three age groups: less than or equal to five yr (n = 18), 6-12 yr (n = 18), and 13-17 yr (n = 25). The dosing regimen was daclizumab 1.0 mg/kg before transplantation, followed by four biweekly doses. The pharmacokinetics of daclizumab were described using NONMEM software. Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 μg/mL (2.48-8.78), 4.54 μg/mL (1.79-18.7), and 4.94 μg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively. Steady-state median (range) daclizumab exposures were 2040 mg·h/mL (1585-3778), 2757 mg·h/mL (1873-3494) and 3297 mg·h/mL (1705-6453), respectively. Saturation of the IL-2R occurred rapidly and was maintained for greater than or equal to three months after transplantation. Daclizumab was generally well-tolerated with no acute allergic or anaphylactic reactions, deaths or malignancies during the study. The proportion of patients who developed acute rejection at six and 12 months was 8.5% and 16.7%, respectively. This study shows that adding daclizumab at 1 mg/kg to standard immunosuppressive therapy provides safe and effective IL-2R blockade.

AB - This study examined the safety and pharmacokinetics/pharmacodynamics of daclizumab in combination with mycophenolate mofetil (or azathioprine), corticosteroids, and cyclosporine or tacrolimus, in 61 pediatric renal allograft recipients in three age groups: less than or equal to five yr (n = 18), 6-12 yr (n = 18), and 13-17 yr (n = 25). The dosing regimen was daclizumab 1.0 mg/kg before transplantation, followed by four biweekly doses. The pharmacokinetics of daclizumab were described using NONMEM software. Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 μg/mL (2.48-8.78), 4.54 μg/mL (1.79-18.7), and 4.94 μg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively. Steady-state median (range) daclizumab exposures were 2040 mg·h/mL (1585-3778), 2757 mg·h/mL (1873-3494) and 3297 mg·h/mL (1705-6453), respectively. Saturation of the IL-2R occurred rapidly and was maintained for greater than or equal to three months after transplantation. Daclizumab was generally well-tolerated with no acute allergic or anaphylactic reactions, deaths or malignancies during the study. The proportion of patients who developed acute rejection at six and 12 months was 8.5% and 16.7%, respectively. This study shows that adding daclizumab at 1 mg/kg to standard immunosuppressive therapy provides safe and effective IL-2R blockade.

KW - Children

KW - Immunosuppression

KW - Interleukin 2 receptor

KW - Kidney transplantation

KW - Monoclonal antibody

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=43249098549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249098549&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2007.00830.x

DO - 10.1111/j.1399-3046.2007.00830.x

M3 - Article

VL - 12

SP - 447

EP - 455

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 4

ER -